Literature DB >> 29050069

[miR-449a is a potential epigenetic biomarker for WNT subtype of medulloblastoma].

Y X Li1, L W Shao, T Jiang, Y Liu, Q Chang.   

Abstract

Objective: To identify the candidate epigenetic biomarkers of Wnt subtype of medulloblastoma(MB).
Methods: MicroRNAs(miRNAs) expression array was used to detect the expression of miRNAs in MB cell lines with or without treatment by demethylation reagent. Nanostring gene expression array was used to detect the expression level of mRNA in 45 samples of primary MB. Molecular subtyping was performed based on the NanoString data. The status of methylation was confirmed by methylation specific PCR. The expression of candidate miRNA was confirmed by real-time PCR.
Results: All 45 MBs except one were classified into the four molecular groups: 4 in WNT group, 8 in SHH group, 16 were in Group3 and 16 in Group4. Methylation specific PCR (MSP) assay confirmed miR-449a was silenced due to aberrant DNA methylation in MB cell lines.WNT subtype of MBs showed relatively higher expression of miR-449a comparing with other subgroups.
Conclusion: MiR-449a, a candidate tumor suppressor gene regulated by hypermethylation, is a novel potential epigenetic marker for WNT subtype of MBs.

Entities:  

Keywords:  DNA methylation; Medulloblastoma; MicroRNAs; Molecular typing

Mesh:

Substances:

Year:  2017        PMID: 29050069     DOI: 10.3760/cma.j.issn.0529-5807.2017.10.005

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  1 in total

1.  Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions.

Authors:  Musa Alharbi; Nahla Mobark; Yara Bashawri; Leen Abu Safieh; Albandary Alowayn; Rasha Aljelaify; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Ebtehal AlSolme; Maqsood Ahmad; Ayman Al-Banyan; Fahad E Alotabi; Jonathan Serrano; Matija Snuderl; May Al-Rashed; Malak Abedalthagafi
Journal:  Front Neurol       Date:  2020-03-20       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.